Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Today, we explore significant shifts shaping the biotech and pharmaceutical landscape. With Donald Trump’s presidential win, the industry is keenly focused on potential changes in FDA and FTC leadership, especially with Robert F. Kennedy Jr.’s anticipated influence on health policy. Meanwhile, Sana Biotechnology’s strategic pivot toward autoimmune disease research and workforce reductions underscore its evolving priorities. Beam Therapeutics faces challenges in gene therapy trials, spotlighting both the risks and potential of gene editing in rare disease treatment. Novocure celebrates FDA approval for its innovative electric field device in non-small cell lung cancer, advancing non-invasive cancer therapy. At the same time, biotech professionals navigate a competitive job market with fewer roles, and we highlight emerging career paths for life science Ph.D.s outside the lab. Thank you for reading BowTiedBiotech, and don’t forget to share to help grow our community!
📣🎙️ TODAY’S POCAST:
[ 0:07 ] Welcome: Biotech Meets Business
[ 0:42 ] FDA Shakeups Under Trump
[ 1:50 ] RFK Jr. and Pharma Policy
[ 2:15 ] Sana’s Strategic Shift
[ 2:39 ] Beam Therapeutics Trial Setback
[ 3:12 ] Electric Field Therapy for Lung Cancer
[ 3:43 ] Biopharma Market Rebound
[ 4:14 ] Shift to Autoimmune Therapies
[ 5:35 ] Alternative Careers for Ph.D.s
[ 6:04 ] AstraZeneca’s Scandal in China
[ 10:46 ] Gene Editing: Risks and Rewards
[ 12:04 ] Resources: Biotech News & Careers
[ 12:27 ] Connect & Stay Updated
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post